Intelligence

#Biopharmaceuticals #Biotechnology #Mammalian transient protein #Pharmaceutical

Mammalian transient protein expression market players eye opportunities in biopharma

Global mammalian transient protein market revenues are projected to surpass US$ 540 million in 2020, according to a new study by Future Market Insights. The report also states that, innovations in automation and recombinant proteins will support market developments, however, prohibitive costs and complexity to maintain media purity remain challenges. Read More

#Market Reports #News

Accurate affinity profiling of a SARS-CoV-2 antibody in serum

The ability to accurately characterise the immune response against SARS-CoV-2 is of vital importance in managing the current COVID-19 pandemic. Measuring antibody affinity under physiologically relevant conditions in complex mixtures like serum remains challenging but is critically important to furthering our understanding of the immune response and protection window in… Read More

#Resources

#Immuno-oncology #Mouse models #Oncology

Syngeneic mouse models for preclinical immuno-oncology

The advent of immuno-oncology has necessitated changes in the types of animal models used in oncology drug discovery. Syngeneic models—inbred mice bearing an engrafted tumour derived from a genetically identical mouse strain—are invaluable preclinical research tools that enable tumor studies in the context of a complete and functional immune system. Read More

#Resources

#AMR #CDMO #Covid-19 #Immunology / Virology & Vaccines #RNA

Vaccine nationalism, AMR & CDMO expansion ahead for 2021

The new CPhI report looks ahead to a post-pandemic 2021 with pharma manufacturing capacity and payment structures shifting as new sourcing strategies emerge. It explores the potential implications in 2021 of impending vaccine approvals, a new administration in the White House and a return to dual supply chain strategies. The report… Read More

#Business & Investment #Covid-19 #Editor's Choice #Market Reports #News

#Biotechnology #Cell therapy #Covid-19 #Gene therapy #Immunology / Virology & Vaccines #Pharmaceutical

Investment banking head offers market outlook for 2021

The Jefferies Healthcare Temperature Check report is now in its third edition and published to coincide with the 11th annual Global Healthcare Conference which was held virtually. Over 500 responses from senior leaders in the sector responded for this year’s report, giving views on both the current state of the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Market Reports #News #Opinion #Trends & Analysis

#Business #Clinical trials #Therapeutics

Drug launches to drive NASH growth across major markets, says research

Several pharmacological treatments for non-alcoholic steatohepatitis (NASH) are expected to be launched in the seven major markets (7MM*) over the next 10 years. It is anticipated that these products can demand higher prices than the current off-label therapies, considering no therapy has been approved for the indication, and drive strong… Read More

#News #Trends & Analysis

#Covid-19 #Pharmaceutical #Research & development

UK pharma sector R&D spending at 8-year high

R&D spending in the UK pharmaceutical sector has jumped 6.9% annually to an eight-year high, analysis of the latest ONS data by R&D tax relief specialist Catax shows. Total pharmaceutical industry spending on R&D rose to £4.8bn last year, an increase of £306m from the £4.5bn recorded a year earlier1. Read More

#Editor's Choice #News #Trends & Analysis

Live-Cell Analysis Training Video: From Culture to Assay

Cell-based assay research in pharma and academia, depends on forms of measurement of living cells. As soon as cells are placed in culture, there is opportunity to learn about or monitor the cells prior to analysis. Live-Cell Analysis enables real-time analysis with full cell tracking workflows.

#Resources

#AI / data analytics / healthtech / informatics #Alzheimer's #Biomarkers #iLoF

The start-up that knows one size doesn’t fit all

Luis Valente, CEO & Co-Founder of iLoF, has been recognized by Forbes as one of the top 30 under 30 for science and healthcare. He told Lu Rahman what’s behind his start-up that recently secured $1 million in investment from Microsoft’s Venture Fund, M12 and Mayfield Fund and won the… Read More

#Start-up Zone

#Biologics / Biotechnology #Drug discovery #Japan #NGS #PCR

Big in Japan: SPT Labtech spots biotech growth

SPT Labtech recently opened a new office to maximise on Japanese biotech growth. Lu Rahman caught up with Director Masahiro Matsushita, to find out about the region and the opportunities for drug discovery.   LR: Tell me about the company’s experience in the Japanese biotech market in Japan – how… Read More

#Market Reports

#AI / data analytics / healthtech / informatics #Covid-19 #Drug candidates #Drug development #MS #Therapeutics

New for old: the value behind drug repurposing  

Lu Rahman looks at the drug repurposing market. How attractive a proposition is it financially?  More than ever the world is watching drug development and is aware of the time it takes to get a drug to market. The 10-15 years that this can involve is costly, so unsurprisingly,… Read More

#Covid-19 #Exclusive Content #Trends & Analysis

#AstraZeneca #Clinical trials #Covid-19 #Drug discovery #Therapeutics #Vaccines

Where are the opportunities in global drug discovery?

With COVID-19 taking centre stage in global drug discovery, Lu Rahman looks at opportunities ahead for the sector and where attention might be focussed going forward.  It is clear from the current pandemic that opportunities arise within drug discovery and development when we don’t always expect… Read More

#Covid-19 #Exclusive Content #Trends & Analysis

#Covid-19 #Drug development #Drug discovery #Liverpool

Creating a world leading infection R&D hub in the UK

As the world is rocked by one of the greatest healthcare challenges in living memory, how we treat infectious diseases is becoming one of the key medical questions of our age. Hannah Randles, Health and Life Sciences Champion at Liverpool City Region’s Growth Platform explains how the region’s infectious diseases… Read More

#Covid-19 #Exclusive Content #Trends & Analysis

#Covid-19 #Daiichi Sankyo #Drug discovery #Fujifilm Toyama Chemical #Japan #Takeda

Japanese drug development: Where is the innovation? 

Lu Rahman looks at how opportunities are growing in Japanese drug development and where innovation is coming from. Japan is a fascinating drug discovery and development market. A strong pharmaceutical sector (some reports place it second globally behind the US), an ageing population and a tranche of expertise, put the… Read More

#Editor's Choice #Exclusive Content #Market Reports